Skip to main content
. 2021 Dec 27;12(1):34. doi: 10.3390/biom12010034

Figure 2.

Figure 2

Silencing hippocampal RTP801 levels prevents cognitive dysfunction in the R6/1 mouse. (a) AAVs expressing GFP-shCT (AAV-shCt) or GFP-shRNA-RTP801 (AAV-shRTP801) were bilaterally injected in the dorsal hippocampus of 2-month-old WT and R6/1 male mice. A battery of behavioral tests was performed 4 weeks later. (b–d) Locomotor activity in the open field was assessed for 30 min. Total distance travelled each 3 min (b) (two-way ANOVA group effect for travelled distance F(3,32) = 1.767, p = 0.1732), distance travelled in the center (c) (treatment effect: F(1, 33) = 0.1085, p = 0.7439; genotype effect: F(1, 33) = 3.517, p = 0.0696), as a measure of anxiety, and parallel index (d) (treatment effect: F(1, 33) = 0.02069, p = 0.8865; genotype effect: F(1, 33) = 0.2781, p = 0.6015) were monitored. No differences were found between groups. Data are represented as mean ± SEM and were analyzed with two-way ANOVA. (e) Spontaneous alternation rate 2 h after the training trial was assessed in the T-SAT. Chi-square (χ2) test was performed in pair comparisons: * p < 0.05 and **** p < 0.0001 compared with WT shCt and $$$$ p < 0.0001 compared with R6/1 shCt. (f) In the passive avoidance test, the latency (in seconds) to step-through was measured before (training), 24 h after and weekly after training (6 weeks of data are shown in the graph). Data from the 6-week testing day was analyzed with one-way ANOVA (F = 8.542, p = 0.0002) followed by Bonferroni’s post hoc test: * p < 0.05 and *** p < 0.001. Data are means ± SEM.